Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25138958 |
US |
78 | 2 |
Injection site pain, Injection site nodule, Device difficult to use, Drug dose omission by device, Incorrect disposal of product, Accidental exposure to product, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 2 | 25139195 |
US |
2 | |
Glassy eyes, Ocular hyperaemia, Foreign body sensation in eyes, Eye discharge, Product complaint, Circumstance or information capable of leading to medication error, Accidental exposure to product, Exposure via skin contact, Liquid product physical issue, Wrong product administered, |
||||
PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, |
||||
| 3 | 25139268 |
US |
78 | 2 |
Device difficult to use, Drug dose omission by device, Wrong technique in product usage process, Injection site indentation, Accidental exposure to product, Discomfort, |
||||
EVOLOCUMAB, |
||||
| 4 | 25139274 |
US |
61 | 2 |
Eye disorder, Accidental exposure to product, Exposure via skin contact, Liquid product physical issue, Wrong technique in product usage process, Product knowledge deficit, Poor quality product administered, Product complaint, |
||||
PERFLUOROHEXYLOCTANE, |
||||
| 5 | 25139413 |
US |
61 | 2 |
Device deployment issue, Injection site haemorrhage, Accidental exposure to product, Incorrect dose administered by device, Arthritis, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 6 | 25139816 |
HR |
||
Loss of consciousness, Accidental exposure to product, |
||||
QUETIAPINE FUMARATE, QUETIAPINE, CLONAZEPAM, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, BUPROPION HYDROCHLORIDE, BUPROPION, |
||||
| 7 | 25140730 |
US |
65 | 1 |
Accidental exposure to product, |
||||
BELIMUMAB, |
||||
| 8 | 25141070 |
US |
70 | 2 |
Arthritis, Accidental exposure to product, Wrong technique in product usage process, Drug dose omission by device, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 9 | 25141403 |
US |
2 | 1 |
Dermatitis atopic, Dry skin, Skin exfoliation, Therapeutic response shortened, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 10 | 25141467 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 11 | 25141484 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
DUPILUMAB, |
||||
| 12 | 25141572 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 13 | 25141580 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 14 | 25141626 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 15 | 25141627 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ALENDRONATE SODIUM, CARVEDILOL, DICLOFENAC EPOLAMINE, FOSINOPRIL SODIUM, FOSINOPIRL SODIUM, FOSINOPRIL, LEVOTHYROXINE, SPIRONOLACTONE, |
||||
| 16 | 25141705 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 17 | 25141913 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 18 | 25142262 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 19 | 25142378 |
US |
75 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ALBUTEROL SULFATE, AMLODIPINE BESYLATE, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, SIMVASTATIN, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 20 | 25142523 |
US |
9 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 21 | 25138119 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 22 | 25138163 |
US |
57 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 23 | 25138272 |
US |
39 | |
Escherichia infection, Injection site reaction, Accidental exposure to product, Device deployment issue, |
||||
GUSELKUMAB, |
||||
| 24 | 25138327 |
FR |
52 | 2 |
Crohn^s disease, Accidental exposure to product, Device issue, Product dose omission issue, Off label use, Eye inflammation, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 25 | 25138351 |
US |
||
Needle issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 26 | 25138436 |
US |
41 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 27 | 25138454 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 28 | 25138678 |
US |
37 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 29 | 25137545 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 30 | 25137590 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 31 | 25137810 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 32 | 25137818 |
US |
43 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 33 | 25137883 |
US |
2 | |
Exposure via skin contact, Product dose omission issue, Wrong technique in device usage process, Accidental exposure to product, |
||||
BELIMUMAB, |
||||
| 34 | 25137929 |
US |
14 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 35 | 25132056 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 36 | 25132172 |
US |
68 | 2 |
Therapy non-responder, Device difficult to use, Accidental exposure to product, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 37 | 25132193 |
CN |
||
Acute myocardial infarction, Device difficult to use, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 38 | 25132211 |
US |
60 | 1 |
Rhinorrhoea, Back pain, Pain in extremity, Myalgia, Device difficult to use, Product communication issue, Drug dose omission by device, Accidental exposure to product, |
||||
EVOLOCUMAB, METOPROLOL TARTRATE, METOPROLOL, LOSARTAN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ERGOCALCIFEROL, |
||||
| 39 | 25132293 |
US |
||
Accidental exposure to product, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 40 | 25132298 |
US |
77 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 41 | 25132432 |
US |
69 | |
Accidental exposure to product, Product dose omission issue, Blood disorder, |
||||
TEZEPELUMAB-EKKO, |
||||
| 42 | 25132492 |
US |
62 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 43 | 25132835 |
US |
42 | 2 |
Device defective, Needle issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 44 | 25133206 |
US |
2 | |
Accidental exposure to product, Product dose omission issue, Device malfunction, Device leakage, |
||||
SECUKINUMAB, GABAPENTIN, DULOXETINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, MIRTAZAPINE, |
||||
| 45 | 25133397 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 46 | 25133434 |
US |
44 | 2 |
Accidental exposure to product, |
||||
FREMANEZUMAB-VFRM, |
||||
| 47 | 25133470 |
US |
36 | 2 |
Product dose omission issue, Accidental exposure to product, Device issue, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 48 | 25133719 |
US |
||
Accidental exposure to product, Wrong technique in product usage process, |
||||
DICLOFENAC, DICLOFENAC SODIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 49 | 25133733 |
US |
2 | |
Device leakage, Needle issue, Drug dose omission by device, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 50 | 25133914 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 51 | 25133920 |
US |
28 | 2 |
Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 52 | 25134041 |
US |
22 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 53 | 25134050 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 54 | 25134097 |
US |
8 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 55 | 25134300 |
FI |
74 | 2 |
Seizure, Exposure via partner, Accidental exposure to product, Chills, Paraesthesia, Hypoaesthesia, Blood pressure increased, |
||||
| 56 | 25134859 |
US |
78 | 2 |
Injection site haemorrhage, Fall, Off label use, Accidental exposure to product, Vitamin D decreased, Product dose omission issue, Device issue, |
||||
OMALIZUMAB, ROSUVASTATIN, LEVOTHYROXINE, LOSARTAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, HYDROXYZINE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, CLONAZEPAM, |
||||
| 57 | 25135251 |
US |
63 | 1 |
General physical health deterioration, Wrong technique in product usage process, Accidental exposure to product, Device leakage, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 58 | 25135343 |
BG |
2 | |
Device deployment issue, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
| 59 | 25135352 |
US |
12 | 1 |
Device difficult to use, Accidental exposure to product, Incorrect dose administered by device, Therapeutic product effect incomplete, Off label use, Migraine, Therapeutic response shortened, Wrong technique in product usage process, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, GALCANEZUMAB-GNLM, RIMEGEPANT SULFATE, |
||||
| 60 | 25135573 |
US |
55 | 2 |
Product preparation error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 61 | 25135597 |
CN |
32 | 1 |
Device deployment issue, Injection site pain, Injection site haemorrhage, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 62 | 25135767 |
US |
2 | |
Accidental exposure to product, Product packaging issue, |
||||
HYDROCORTISONE AND ACETIC ACID OTIC, HYDROCORTISONE AND ACETIC ACID, |
||||
| 63 | 25136098 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 64 | 25136116 |
US |
67 | 2 |
Wheezing, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 65 | 25136753 |
US |
||
Application site infection, Accidental exposure to product, |
||||
RUXOLITINIB, |
||||
| 66 | 25136793 |
US |
1 | |
Accidental exposure to product, Product dose omission issue, Device issue, |
||||
SECUKINUMAB, |
||||
| 67 | 25136794 |
US |
62 | 1 |
Drug dose omission by device, Accidental exposure to product, Needle issue, Incorrect dose administered by device, |
||||
SECUKINUMAB, |
||||
| 68 | 25126312 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 69 | 25126368 |
US |
56 | 1 |
Scratch, Exposure via skin contact, Device use error, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 70 | 25126517 |
US |
66 | 2 |
Accidental exposure to product, Device difficult to use, Product communication issue, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 71 | 25127011 |
US |
1 | |
Incorrect dose administered, Accidental exposure to product, Device issue, |
||||
BIMEKIZUMAB, |
||||
| 72 | 25127803 |
US |
66 | 1 |
Accidental exposure to product, Drug dose omission by device, Visual impairment, Off label use, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 73 | 25127990 |
US |
||
Accidental exposure to product, Eye irritation, |
||||
ESKETAMINE HYDROCHLORIDE, |
||||
| 74 | 25128650 |
US |
||
Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 75 | 25128654 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 76 | 25128677 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 77 | 25128678 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 78 | 25128680 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 79 | 25128711 |
US |
2 | |
Injection site rash, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 80 | 25128718 |
US |
58 | 1 |
Oropharyngeal pain, Nasopharyngitis, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 81 | 25128793 |
US |
50 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 82 | 25128862 |
US |
62 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 83 | 25128870 |
US |
56 | 1 |
Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 84 | 25128914 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 85 | 25128933 |
US |
40 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 86 | 25128982 |
US |
12 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 87 | 25129382 |
US |
84 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 88 | 25129386 |
US |
74 | 2 |
Injection site swelling, Injection site bruising, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 89 | 25129444 |
US |
43 | 2 |
Product dose omission issue, Device issue, Accidental exposure to product, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, CYCLOSPORINE, CYCLOSPORINE, FAMOTIDINE, CETIRIZINE HYDROCHLORIDE, |
||||
| 90 | 25129875 |
BR |
||
Accidental exposure to product, Device deployment issue, |
||||
PEGFILGRASTIM, |
||||
| 91 | 25130506 |
US |
85 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 92 | 25130779 |
CN |
||
Disease recurrence, Nasopharyngitis, Exposure via skin contact, Incorrect dose administered, Accidental exposure to product, Off label use, Product complaint, |
||||
MEPOLIZUMAB, MEPOLIZUMAB, MEPOLIZUMAB, |
||||
| 93 | 25131018 |
US |
72 | 2 |
Exposure via skin contact, Device use error, Accidental exposure to product, |
||||
BELIMUMAB, |
||||
| 94 | 25131376 |
BR |
||
Needle issue, Accidental exposure to product, |
||||
GOLIMUMAB, |
||||
| 95 | 25131564 |
US |
2 | |
Accidental exposure to product, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 96 | 25131942 |
US |
64 | |
Product storage error, Accidental exposure to product, Memory impairment, Inappropriate schedule of product administration, |
||||
GUSELKUMAB, |
||||
| 97 | 25121189 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 98 | 25121200 |
US |
39 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 99 | 25121206 |
US |
56 | 2 |
Factor V Leiden mutation, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 100 | 25121253 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, CLONIDINE, LEVALBUTEROL TARTRATE, EPINEPHRINE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, DEXLANSOPRAZOLE, MOMETASONE FUROATE, FEXOFENADINE HYDROCHLORIDE, MONTELUKAST SODIUM, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28